Patrick J. Heron - 04 Jun 2025 Form 4 Insider Report for Arcutis Biotherapeutics, Inc. (ARQT)

Reporting relationship: Director
Issuer ticker: ARQT
Reported as of: 04 Jun 2025
Net transaction value: +$30,247
SEC form: 4
Accepted by SEC: 06 Jun 2025, 08:44:37 UTC
Prior SEC filing: 02 Jun 2025
Next SEC filing: 06 Jun 2025
Source filing: View source filing
Reporting owner signature: /s/ Steve R. Bailey, Attorney-in-Fact For Patrick J. Heron

Key filing fact

Patrick J. Heron filed Form 4 for Arcutis Biotherapeutics, Inc. (ARQT) on 06 Jun 2025.

Key facts

This page summarizes Patrick J. Heron's Form 4 filing for Arcutis Biotherapeutics, Inc. (ARQT).
2 reported transactions and 0 derivative rows are listed below.
Accepted by SEC: 06 Jun 2025, 08:44.

Change

Previous filing in this sequence was filed on 02 Jun 2025.
Current net transaction value: +$30,247.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001365617 Primary reporting owner

Heron Patrick J

Relationship: Director
Address: 1001 PAGE MILL RD, BUILDING 4, SUITE B, PALO ALTO
Signature: /s/ Steve R. Bailey, Attorney-in-Fact For Patrick J. Heron
Signature date: 06 Jun 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ARQT transaction

Common Stock

Purchase

Transaction value: $25,177
Shares: +1,890
Change %: +8.4%
Price: $13.32
Shares after: 24,424
Date: 04 Jun 2025
Ownership: By Frazier Life Sciences X, L.P.
Footnotes: F1, F2

ARQT transaction

Common Stock

Purchase

Transaction value: $5,069
Shares: +378
Change %: +1.5%
Price: $13.41
Shares after: 24,802
Date: 05 Jun 2025
Ownership: By Frazier Life Sciences X, L.P.
Footnotes: F2, F3

ARQT holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 8,785,284
Date: 04 Jun 2025
Ownership: By Frazier Life Sciences VIII, L.P.
Footnotes: F4

ARQT holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 7
Date: 04 Jun 2025
Ownership: By FHM Life Sciences VIII, L.L.C.
Footnotes: F5

ARQT holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 23,688
Date: 04 Jun 2025
Ownership: By The Heron Living Trust 11/30/2004
Footnotes: F6

ARQT holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 18,826
Date: 04 Jun 2025
Ownership: Direct

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 6 footnotes

Footnote F1

The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $13.26 to $13.35, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (1) to this Form 4.

Footnote F2

The shares reported herein are held of record by Frazier Life Sciences X, L.P. FHMLS X, L.P. is the general partner of Frazier Life Sciences X, L.P. and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. The Reporting Person is one of two managing members of FHMLS X, L.L.C. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.

Footnote F3

The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $13.21 to $13.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (3) to this Form 4.

Footnote F4

The shares reported herein are held of record by Frazier Life Sciences VIII, L.P. FHM Life Sciences VIII, L.P. is the general partner of Frazier Life Sciences VIII, L.P. and FHM Life Sciences VIII, L.L.C. is the general partner of FHM Life Sciences VIII, L.P. The Reporting Person is one of two managing members of FHM Life Sciences VIII, L.L.C. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.

Footnote F5

The shares reported herein are held of record by FHM Life Sciences VIII, L.L.C. The Reporting Person is one of two managing members of FHM Life Sciences VIII, L.L.C. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.

Footnote F6

The shares are held directly by The Heron Living Trust 11/30/2004. The Reporting Person is the co-trustee of The Heron Living Trust 11/30/2004 and has voting and investment power of the securities held by The Heron Living Trust 11/30/2004.